RecruitingNCT06350734
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Sponsor
Mayo Clinic
Enrollment
704 participants
Start Date
Oct 12, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the effect of bladder cancer treatment on quality of life.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Have pathologically confirmed, clinically localized, bladder cancer
- Be willing to complete a survey in English before starting definitive treatment (surgery or radiation);
- Able to give consent.
Interventions
OTHERNon-Interventional Study
Non-Interventional Study
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06350734
Related Trials
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582113 locations
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
NCT07061964123 locations
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
NCT061733491 location
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
NCT058434481 location
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
NCT073022301 location